To provide proof-of-concept and test whether nucleoside-modified VEGFC mRNA-LNP treatment influences disease progression in an experimental lymphedema system, we assessed the present platform in a recently developed Diphtheria toxin-inducible genetic secondary lymphedema mouse model45,46. This evidence concerns the gene VEGFC and lymphedema.